Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. [electronic resource]
Producer: 20100614Description: 152-6 p. digitalISSN:- 1873-2496
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Clinical Trials, Phase II as Topic
- Docetaxel
- Drug Resistance, Neoplasm -- drug effects
- Estramustine -- administration & dosage
- Humans
- Male
- Middle Aged
- Prostate-Specific Antigen -- blood
- Prostatic Neoplasms -- drug therapy
- Randomized Controlled Trials as Topic
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial; Journal Article
There are no comments on this title.
Log in to your account to post a comment.